SCHEMBL5153801

SCHEMBL5153801

CC1CC(=S)N1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13729295 0.71 CREBBP (0.62)
SCHEMBL12160740 0.69
SCHEMBL6977167 0.67
SCHEMBL20614486 0.67 CREBBP (0.52)
SCHEMBL22187093 0.66
Iodide SCHEMBL11013396 0.65
SCHEMBL17472516 0.65
SCHEMBL13104083 0.63
SCHEMBL14469208 0.63
SCHEMBL13213163 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1560649-A4 ACTIVE CATALYSTS FOR STEREOSELECTIVE RING-OPENING REACTIONS RHODIA PHARMA SOLUTION INC (US) 2007-05-02 EP disclosed
EP-1534699-A4 KINETIC RESOLUTION METHOD RHODIA PHARMA SOLUTIONS INC (US) 2007-01-10 EP disclosed
EP-1560649-A1 ACTIVE CATALYSTS FOR STEREOSELECTIVE RING-OPENING REACTIONS Rhodia Pharma Solution Inc. (US) 2005-08-10 EP disclosed
EP-1534699-A1 KINETIC RESOLUTION METHOD Rhodia Pharma Solutions Inc. (US) 2005-06-01 EP disclosed
US-6781006-B2 Active catalysts for stereoselective ring-opening reactions RHODIA PHARMA SOLUTIONS INC. 2004-08-24 US disclosed
WO-2004026469-A1 ACTIVE CATALYSTS FOR STEREOSELECTIVE RING-OPENING REACTIONS RHODIA PHARMA SOLUTIONS INC. (US) 2004-04-01 WO disclosed
US-20040053779-A1 Active catalysts for stereoselective ring-opening reactions SHASUN PHARMA SOLUTIONS, INC. 2004-03-18 US disclosed
WO-2004020429-A1 KINETIC RESOLUTION METHOD RHODIA PHARMA SOLUTIONS INC. (US) 2004-03-11 WO disclosed
US-6639087-B2 Reacting a nucleophile and a chiral or prochiral cyclic substrate in the presence of a chiral, nonracemic catalyst; changing the oxidation state of catalyst residue to prevent degradation of product mixture; stereospecific RHODIA PHARMA SOLUTIONS INC. 2003-10-28 US disclosed
US-20030088114-A1 Kinetic resolution method SHASUN PHARMA SOLUTIONS, INC. 2003-05-08 US disclosed